Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "PHARMA"


25 mentions found


Morgan Stanley raised its price target on Nvidia, calling for more than 15% upside going forward. — Lisa Kailai Han 5:53 a.m.: Jefferies lowers Tesla price target, cites 'self-inflicted' wounds Tesla's troubles may not be over yet, according to Jefferies. The investment firm kept its hold rating on the electric vehicle maker and lowered its price target to $165 from $185. Jefferies analyst Philippe Houchois also said Tesla is plagued by shifting product priorities. — Lisa Kailai Han 5:53 a.m.: Morgan Stanley raises Nvidia price target Nvidia has already rallied more than 72% in 2024.
Persons: Morgan Stanley, Jefferies, Patrick Cunningham, Erik Fyrwald's, Cunningham, — Lisa Kailai Han, Zillow, John Colantuoni, Colantuoni, Scott Schoenhaus, Schoenhaus, Lisa Kailai Han, Hess, Betty Jiang, CVX, Jiang, Tesla, Philippe Houchois, Joseph Moore, Moore, — Fred Imbert Organizations: CNBC, Nvidia, Citi, Management, & Biosciences, Jefferies, National Association of Realtors, Markets, GDRX, Barclays, Chevron, NVIDIA, AMD Locations: Tuesday's, China
"INFLATION is BACK—and RAGING!," the former president wrote in a Truth Social post. "The Fed will never be able to credibly lower interest rates, because they want to protect the worst President in the history of the Untied States!" "I'm calling on corporations, including grocery retailers, to use record profits to reduce prices," Biden said in a statement following the CPI report. "Congressional Republicans want to slash taxes for billionaires and big corporations, while helping special interests and Big Pharma raise prices. Biden has continually blamed big corporations and Republicans for the lingering high costs of living that consumers still report feeling while touting economic gains from his own policies.
Persons: Donald Trump, Joe Biden, Biden Organizations: Federal Reserve, Congressional, Big Pharma
CNN —As the first over-the-counter birth control pill in the United States hits store shelves, the company behind the product, Perrigo, is taking steps to ensure women are aware of this new contraception option. It’s a different formulation than what is in combination hormonal birth control pills, which contain both progestin and estrogen. Combined birth control pills may carry risks for people with uncontrolled hypertension or blood clot risks for smokers older than 35. Most birth control pills are up to 99% effective at preventing pregnancy if taken as instructed. “I’m always a little skeptical of Big Pharma and their partnerships, but I think the general principle of having highly effective over-the-counter birth control be over the counter, that’s empowering” she said.
Persons: “ We’re, Opill, , Colie Edison, “ We’ve, Leila Bahbah, ” Edison, “ we’re, , , , Roe, Wade, prescribers, Joe Biden, Dobbs, Dr, Sanjay Gupta, Colleen Denny, Denny, “ I’m, ” Denny Organizations: CNN, WNBA, , ESPN, US Food and Drug Administration, Jackson, Health Organization, White, Get CNN, CNN Health, NYU Langone Hospital –, Big Pharma Locations: United States, Dobbs v,
Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are all the rage, and investors are noticing. Since launching in November, the Tema Obesity and Cardiometabolic ETF (HRTS) is up 24%, crushing the S&P 500's 14.8% returns over the same period. Pot and his colleagues at Tema are bullish on the weight-loss drug stocks due to the wave of demand they see coming. Novo Nordisk estimates that only 2% of obesity cases are being treated by weight-loss drugs, Pot said. 4 weight-loss drug stocks to watchPot listed two larger stocks and two smaller ones in the space.
Persons: Maurits Pot, Janus Henderson, Pot, Goldman Sachs, Geoff Meacham, Charles Barkley, Elon Musk, Whoopi Goldberg, Eli Lilly, Lilly Organizations: VanEck Pharmaceutical, Business, World Health Organization, Novo Nordisk, Bank of America, Bank, Nordisk, FDA, Amazon, Therapeutics, Zealand Pharma Locations: Tema, GLP, Danish, it's
In the hours before delivering his State of the Union speech last month, President Biden called the chief executives of General Motors and Cisco Systems to ask their advice on the state of the American economy and share how he planned to talk about it. Then he rode to Capitol Hill and, in his address, promised to raise the rate on a new minimum tax his administration has levied on big companies “so every big corporation finally begins to pay their fair share.”“I also want to end tax breaks for Big Pharma, Big Oil, private jets, massive executive pay,” Mr. Biden continued, adding: “End it now.”The sequence epitomizes Mr. Biden’s alternatively cozy and combative relationship with America’s business leaders, which has rippled through the national economy, federal policy and now the 2024 campaign for the White House.
Persons: Biden, ” “, Mr Organizations: General Motors, Cisco Systems, Capitol, Big Pharma, Big Oil, White
Yet those numbers are reversed when asked to rate the state’s economy. In Wisconsin, negative views of the national economy outweigh positive ones by 16 points, while positive views of the state economy outweigh negative ones by 17 points. Across these battleground states, 46% of registered voters said their personal financial situation is headed in the right direction. Now, more than half of registered voters in the Wall Street Journal poll of battleground states said they either strongly or somewhat approve of the job Trump did as president. Biden is neck-and-neck with Trump among registered voters in those seven swing states on the question of protecting democracy.
Persons: Joe Biden, Donald Trump, Larry Summers, Summers, Biden, Ariel Edwards, Levy, Edwards, “ People’s, , It’s, Trump, Biden’s, Joe, Jill Biden, Robert F, Kennedy Jr, “ He’s, ” Jill Biden, Will, Sen, Bernie Sanders, Sanders “, George W, – Trump’s, Bush Organizations: CNN — Voters, Wall Street, Biden, Treasury, Federal Reserve, Gallup, Journal, Street, CBS, Vermont, White, Big Pharma, Medicare, CNN, Republican, Trump, Capitol Locations: Arizona, Georgia, Michigan, North Carolina , Nevada , Pennsylvania, Wisconsin, North Carolina, brag, Iraq
James Carville said RFK Jr.'s White House bid could be more of a drag on Trump than Biden. RFK Jr. said last week that his candidacy would be a "spoiler" for both Biden and Trump. Related storiesIn recent polling of three-way matchups between Biden, Trump, and Kennedy Jr., the former president is often slightly ahead. "Our campaign is a spoiler all right," Kennedy Jr. said during an event last week welcoming Shanahan to the ticket. Carville, who warned about cracks in the Democratic Party's electoral foundation, also expressed concern about the presidential campaigns of Cornel West and Jill Stein.
Persons: James Carville, Biden, Bobby Kennedy, Trump, MSNBC's Ari Melber, , Robert F, Kennedy Jr, Donald Trump's, Kennedy, Ari Melber, Nicole Shanahan, Shanahan, New York Sen, Carville, Cornel West, Jill Stein, they're Organizations: RFK, Trump, Biden, Service, Democratic, MSNBC, Big, Big Tech, Big Pharma, New, Cornel Locations: New York
Bernie Sanders wants to make Ozempic cheaper
  + stars: | 2024-03-28 | by ( Geoff Weiss | ) www.businessinsider.com   time to read: +2 min
Sen. Bernie Sanders said the price of Ozempic is "outrageously high." A recent study found that Ozempic can be made for less than $5 per month — but it costs nearly $1,000. AdvertisementSen. Bernie Sanders is outraged by the price of Ozempic — so much that he wants to meet with the CEO of its maker, pharma giant Novo Nordisk, Bloomberg reports. Related stories"A new Yale study found that Ozempic costs less than $5 a month to manufacture," Sanders said in a statement. Novo Nordisk also spent $5 billion on R&D globally in 2023, the company said.
Persons: Sen, Bernie Sanders, , Sanders, Lars Fruergaard Jørgensen, Sanders — Organizations: Novo Nordisk's, Bloomberg, Service, pharma, Novo Nordisk, Health, Education, Labor, Yale, Nordisk Locations: Novo, GLP, Canada, Germany, U.S, America
Here are Thursday's biggest calls on Wall Street: Wells Fargo reiterates Bank of America as overweight Wells Fargo raised its price target on Bank of America to $44 per share from $40. HSBC downgrades Bank of America to hold from buy HSBC downgraded Bank of America mainly on valuation. Benchmark reiterates Nvidia as buy Benchmark said it's standing by its buy rating on Nvidia. Bank of America reiterates Amazon as buy Bank of America said it's bullish on Amazon's investments in AI. "We are initiating coverage on CYBR with a Buy rating and a $317 PT."
Persons: Wells Fargo, Bernstein, it's, Goldman Sachs, Tesla, Goldman, Piper Sandler, Piper, Clark, Kimberly, Claude, Estee Lauder, BTIG, TD Cowen, Cowen, Grindr, William Blair, Bentley, Morgan Stanley, JPMorgan, KeyBanc, Oppenheimer, Monness Crespi Hardt downgrades Palantir, Palantir Organizations: Bank of America, FDIC, Apple, HSBC downgrades Bank of America, HSBC, of America, PNC, Tesla, EV, Kimberly, Nvidia, Amazon, Bentley Systems, Allstate, JPMorgan, Major Pharma, Citi, Boeing, Barclays, Meta, SNAP Locations: mkts, DraftKings
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The condition refers to when the small blood vessels in the lungs narrow. He noted that the drug will be a "paradigm shift" for patients living with PAH. That includes reducing the risk of death or worsening of the condition by 84% compared to an existing drug alone. Those trials include late-stage studies on patients with more advanced PAH disease, and those who are within the first year after diagnosis.
Persons: Chris Schott, Eliav Barr, PAH, Barr, Merck Organizations: Merck, Drug Administration, JPMorgan, CNBC, Acceleron Pharma Locations: Rahway , New Jersey, U.S, Winrevair
But with his latest startup, Cherish Health, he's taking a different approach. To date, Cherish Health, which makes a radar-based device to detect falls in the home, has raised $26 million from these alternative sources. Cherish Health is now gearing up to raise its Series B round, targeting $30 million at a $200 million valuation. In late 2022, Cherish Health landed $5 million in Series A funding led by Alarm.com at a $45 million valuation. If Cherish Health had gone the way of traditional venture capital, Nagpal said, "we would've given up most of our value by now."
Persons: Sumit Nagpal, Nagpal, he's, we've, JP Morgan, Health's, Health, Alarm.com, consortiums, aren't Organizations: pharma, Abbott, Business, Accenture, Health, Apple, Comcast, Amazon, Cherish Health Locations: Alere, Haven, Amazon , Berkshire, Alarm.com, VCs
Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion is developing "next-generation" radioconjugates (RCs) to treat cancer. RCs deliver a radioactive isotope directly to cancer cells through precise targeting using molecules and have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. Radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.
Persons: AstraZeneca, Susan Galbraith Organizations: Fusion Pharmaceuticals Inc, Amolyt Pharma, AstraZeneca, Fusion, Oncology, U.S . Food, Drug Administration, FDA Locations: Swedish, U.S, radioconjugates
The "next big thing" in tech will come from sectors such as enabling tech — which includes artificial intelligence and cybersecurity — as well as healthtech, greentech and fintech, UBS said. Here are some names from UBS' list and what it says about each stock. "The medical surgical and neurological business has also returned to strong growth as the pandemic impact fades," the bank said. Broadcom : UBS says that Broadcom boasts a "market-leading" position in semiconductor design. Its greentech picks include French industrial gases and services company Air Liquide , French utility firm Engie , and German chemicals firm Wacker Chemie .
Persons: , Stryker, ASML, — CNBC's Michael Bloom Organizations: UBS, fintech, Baidu, ASML, Broadcom, 5G, Intercontinental Exchange, Mastercard, Air, Wacker Chemie Locations: Wacker
Danish pharma giant Novo Nordisk makes both Ozempic and Wegovy. The novel drugs are also boosting pharma stocks — and Denmark's economy. Advertisement"The pharmaceutical industry has been the main driving force in the Danish economy in both the fourth quarter and for the whole of 2023," the agency said. Genmab, Zealand Pharma, and H. Lundbeck are among the other big Danish pharma firms. AdvertisementSuch businesses were a rare bright spot for Denmark's economy last year because they invested in infrastructure, created jobs, and boosted manufacturing, according to Danske Bank's chief economist Las Olsen.
Persons: , it's, Las Olsen, Olsen Organizations: Danish pharma, Novo Nordisk, Service, Nordisk, Zealand Pharma Locations: Denmark, Danish, Copenhagen
Workers are having to be coached on how to behave in the office as companies implement RTO policies. More than 60% of bosses said they plan to offer etiquette training by 2024, a survey said. "Etiquette is now like a buzzword," etiquette coach Suzy Lins, the self-proclaimed Manners Maven, told Business Insider. "In our view, office etiquette training is vital, not only for newbies but for everyone on the team," Chappell said. "Certain roles require stronger communication skills," Martin, who works at a pharma company, said about the hiring process.
Persons: , Suzy Lins, Manners Maven, Mike Chappell, Chappell, Zers, Manners Maven Lins, Lins, they've, they're, Kevon Martin, he's, Martin, it's Organizations: Service, Employees, pharma
The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.
Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo
Let's analyze how to trade a drug stock that's made a terrific comeback and could have more upside from here. But there's a catch: The price of call options have become too expensive given the rally, so we need to think of lower-cost trade to bet on upside from here. Now that it's traded off those lows and started to outperform the markets, I have a follow-up trade. The trade Options on BMY currently are very expensive, so buying calls are out of the question. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.
Persons: that's, BMY, it's Organizations: Myers Squibb, underperformance, pharma, Bristol Myers Locations: Bristol
Trade Tracker: Amy Raskin trims Berkshire
  + stars: | 2024-03-11 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: Amy Raskin trims BerkshireAmy Raskin, Chevy Chase Trust CIO, joins CNBC's 'Halftime Report' to explain why she's buying American Express, Natera, Accenture and trimming Berkshire, Costco Vertex Pharma and Regeneron.
Persons: Amy Raskin Organizations: Chevy Chase Trust, American Express, Accenture, Costco Vertex Pharma Locations: Berkshire
He's launched a new company, Foundation Health, to help them do that quickly and at a low cost. Foundation aims to make it easy for insurers to set up their own online pharmacies and pharma companies to sell drugs directly to consumers. "The main focus area for us is to help health plans disintermediate PBMs," Afridi said. Foundation Health wants to help customers ditch big PBMsFoundation's software enables a few different things. Finally, direct-to-consumer health companies can plug into Foundation's technology to power their services, instead of building their own pharmacies and hiring doctors.
Persons: Umar Afridi, disruptors, Afridi, He's, disintermediate, Garry Tan, Y, they've, pocketing, Eli Lilly's, Jack Altman Organizations: California, Cuban, Plus, Business, Foundation Health, Foundation, pharma, Alt, Liquid Ventures, Exceptional, Storm Ventures, PageOne Ventures, Federal Trade Commission Locations: drugmakers
Monday, March 11, 2024: Jim Cramer discusses why investors should stay patient on this pharma stockJim and Jeff discuss the overweight call on this pharmaceutical stock. They also talk about the call to buy this consumer staple stock. Finally, they discuss the moves in this oil stock.
Persons: Jim Cramer, Jeff
Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.
Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California
Opinion: The one thing Biden and Trump agree on
  + stars: | 2024-03-10 | by ( Richard Galant | ) edition.cnn.com   time to read: +17 min
We’re looking back at the strongest, smartest opinion takes of the week from CNN and other outlets. That reference to Election Day is perhaps the only line in Trump’s speech that President Joe Biden would agree with. In another America, they would be collegial members of the Presidents Club, bonding over memories of how they overcame their thorniest challenges. “Biden sounded like he’s ready to go toe to toe with former President Donald Trump and win in November. Paul Sracic noted that Biden lost White voters without college degrees by 35 points in 2020.
Persons: CNN — “, Donald Trump, Joe Biden, Franklin D, Biden, , Lincoln, Roosevelt’s, Trump, Joe Biden’s, , Jill Filipovic, Clay Jones, David Gergen, Daniel McCarthy, , ” “ Biden, Ronald Reagan, Bill Clinton, wasn’t, ” Carrie Sheffield, ” Sheffield, “ Joe Biden, Roxanne Jones, “ Biden, Julian Zelizer, White, Paul Sracic, MAGA, Keith L, Magee, Patrick T, Brown, Dobbs, Roe, Wade, , Bill Bramhall, Nick Anderson, Manisha Sinha, ” “, Abraham Lincoln, SCOTUS, Anderson, ” Sinha, Frida Ghitis, David Mark, Trump Drew Sheneman, CNN “, Cupp, Hillary Clinton, “ deplorables, ” Cupp, Bill McGuire, Jason Momoa, Ed Mierzwinski, Elena Sheppard, Kara Alaimo, It’s, Euny Hong, Greta Gerwig’s, Sandra, O’Connor, Jason Kelce, Matt Rourke, Jason Kelce’s, Amy Bass, “ Kelce, ” Bass, Jason, ” Dana Summers, Errol Louis, Liam Kerr, Sinema, Richard Salgado, Levinson Moriarty, Celine Song, Greta Gerwig, Barbie, Justine Triet, Alberto Rodriguez, Jaap Buitendijk, Kate Green, “ Oppenheimer, Noah Berlatsky, “ Barbie, “ It’s, ” Berlatsky, Barbie ’, Bradley Cooper’s, Maestro ’, Christopher Nolan’s ‘ Oppenheimer, clichés, Alexander Payne’s ‘, Organizations: CNN, Super, GOP, Trump, Union, Presidents Club, , Democratic, Twitter, Agency, Tribune, Supreme, Republican Party of, MSNBC, Consumer Financial, US Chamber of Commerce, US, Jason Kelce Philadelphia Eagles, Monday, Pro, Bowl, White, Warner Bros, Everett, Getty Locations: America, Joe Biden’s State, Trump, Washington, United States, Civil, American, New York City, Chicago, Denver, , Paris, France
The S & P 500 Volatility Index finished the week near 15 and is in a clear three- month uptrend from its mid-December low near 12, even as the S & P 500 has gained 10% since then. In fact, Friday the market minimized the headline damage to a mere two-thirds-percent dip in the S & P 500 through its signature rotational impulse. Some indicators — such as speculators remaining net short S & P 500 futures and brokerage strategists' muted index targets — imply the helpful wall of worry is not quite fully scaled. Since then, the S & P has delivered a 16.7% annualized total return, even after two bear markets and two other severe/prolonged corrections. And the S & P is only up 7% from its high 26 months ago, hardly in thin air.
Persons: what's, Eli Lilly, Martin Marietta, Nick Colas, Scott Chronert Organizations: Federal, Nvidia, Costco, pharma, Martin Marietta Materials, Vulcan, 3Fourteen Research, NYSE, Nasdaq, DataTrek, Citi
In today's big story, we're looking at pharma companies' surging stocks and threatening tech darlings thanks to their weight-loss drugs. And it comes despite only 1% of US adults taking weight-loss drugs, according to Bank of America , which predicts that number could rise to 15% by 2035. Weight-loss drugs are also cutting more than just fat. For Wall Street, meanwhile, the equation is much simpler: Getting more people on weight-loss drugs boosts the economy. The trend, which will be powered by cash-rich mega-cap tech companies, is thanks to strong earnings growth, the bank said.
Persons: , Joe Biden, Donald Trump —, Trump, Zhan, Eli Lilly, Tesla, Hannah Latham, Octavio Jones, Christian Rodriguez, Laura MacPherson, Jenny Chang, Rodriguez, they're, Goldman Sachs, Biden, Barry Sternlicht, Fernando Gutierrez, It's, Elon Musk, TikTok, Pete Ryan, RJ Scaringe, Dan DeFrancesco, Hallam Bullock, Jordan Parker Erb, George Glover Organizations: Service, pharma, Business, Tesla, Microsoft, JPMorgan, Pfizer, Novo Nordisk, Bank of America, Nvidia, Companies, Fed, Infrastructure Investment, Alpha, Commission, Elon, EV, Nike, Congress, White, Meta, SXSW Locations: China, US, New York, London
Total: 25